Eventide Asset Management - Q4 2013 holdings

$325 Million is the total value of Eventide Asset Management's 94 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was - .

 Value Shares↓ Weighting
MDVN NewMEDIVATION INC$8,603,000134,800
+100.0%
2.65%
CBI NewCHICAGO BRIDGE & IRON CO N V$8,597,000103,400
+100.0%
2.65%
TRW NewTRW AUTOMOTIVE HLDGS CORP$7,967,000107,100
+100.0%
2.45%
ABBV NewABBVIE INC$7,842,000148,500
+100.0%
2.42%
DYAX NewDYAX CORP$7,803,0001,036,300
+100.0%
2.40%
MIC NewMACQUARIE INFRASTR CO LLCmembership int$7,604,000139,700
+100.0%
2.34%
P103PS NewNPS PHARMACEUTICALS INC$7,368,000242,700
+100.0%
2.27%
UFS NewDOMTAR CORP$7,283,00077,200
+100.0%
2.24%
MEOH NewMETHANEX CORP$7,168,000121,000
+100.0%
2.21%
RHT NewRED HAT INC$7,078,000126,300
+100.0%
2.18%
LGND NewLIGAND PHARMACEUTICALS INC$7,069,000134,400
+100.0%
2.18%
PCYC NewPHARMACYCLICS INC$7,045,00066,600
+100.0%
2.17%
LEA NewLEAR CORP$7,028,00086,800
+100.0%
2.16%
MGA NewMAGNA INTL INC$6,663,00081,200
+100.0%
2.05%
WBC NewWABCO HLDGS INC$6,632,00071,000
+100.0%
2.04%
LYB NewLYONDELLBASELL INDUSTRIES N$6,607,00082,300
+100.0%
2.04%
NVAX NewNOVAVAX INC$6,591,0001,287,300
+100.0%
2.03%
LLTC NewLINEAR TECHNOLOGY CORP$6,536,000143,500
+100.0%
2.01%
LOW NewLOWES COS INC$6,531,000131,800
+100.0%
2.01%
PANW NewPALO ALTO NETWORKS INC$6,529,000113,600
+100.0%
2.01%
SCTY NewSOLARCITY CORP$6,477,000114,000
+100.0%
2.00%
OII NewOCEANEERING INTL INC$6,452,00081,800
+100.0%
1.99%
EOG NewEOG RES INC$6,344,00037,800
+100.0%
1.95%
BWA NewBORGWARNER INC$6,295,000112,600
+100.0%
1.94%
KAR NewKAR AUCTION SVCS INC$6,282,000212,600
+100.0%
1.94%
CLDX NewCELLDEX THERAPEUTICS INC NEW$6,222,000257,000
+100.0%
1.92%
AYR NewAIRCASTLE LTD$6,179,000322,500
+100.0%
1.90%
SDRL NewSEADRILL LIMITED$5,887,000143,300
+100.0%
1.81%
CPN NewCALPINE CORP$5,804,000297,500
+100.0%
1.79%
NRG NewNRG ENERGY INC$5,554,000193,400
+100.0%
1.71%
FC NewFRANKLIN COVEY CO$5,403,000271,800
+100.0%
1.66%
WAB NewWABTEC CORP$5,392,00072,600
+100.0%
1.66%
NewASPEN TECHNOLOGY INC$5,371,000128,500
+100.0%
1.66%
STKL NewSUNOPTA INC$5,345,000534,000
+100.0%
1.65%
AGIO NewAGIOS PHARMACEUTICALS INC$5,001,000208,800
+100.0%
1.54%
ASML NewASML HOLDING N V$4,872,00052,000
+100.0%
1.50%
SUNEQ NewSUNEDISON INC$4,866,000372,900
+100.0%
1.50%
PTLA NewPORTOLA PHARMACEUTICALS INC$4,462,000173,300
+100.0%
1.38%
IPHI NewINPHI CORP$4,413,000342,100
+100.0%
1.36%
ACAD NewACADIA PHARMACEUTICALS INC$4,383,000175,400
+100.0%
1.35%
PBYI NewPUMA BIOTECHNOLOGY INC$4,359,00042,100
+100.0%
1.34%
STML NewSTEMLINE THERAPEUTICS INC$4,079,000208,100
+100.0%
1.26%
NOV NewNATIONAL OILWELL VARCO INC$3,778,00047,500
+100.0%
1.16%
SJM NewSMUCKER J M CO$3,741,00036,100
+100.0%
1.15%
NLNK NewNEWLINK GENETICS CORP$3,462,000157,300
+100.0%
1.07%
CCI NewCROWN CASTLE INTL CORP$3,290,00044,800
+100.0%
1.01%
CMRE NewCOSTAMARE INC$3,192,000174,700
+100.0%
0.98%
SGMO NewSANGAMO BIOSCIENCES INC$3,018,000217,300
+100.0%
0.93%
SRPT NewSAREPTA THERAPEUTICS INC$2,888,000141,800
+100.0%
0.89%
SZYM NewSOLAZYME INC$2,627,000241,200
+100.0%
0.81%
PWR NewQUANTA SVCS INC$2,496,00079,100
+100.0%
0.77%
DWSN NewDAWSON GEOPHYSICAL CO$2,208,00065,300
+100.0%
0.68%
TSLA NewTESLA MTRS INC$2,150,00014,300
+100.0%
0.66%
SAAS NewINCONTACT INC$1,510,000193,300
+100.0%
0.46%
COG NewCABOT OIL & GAS CORP$1,364,00035,200
+100.0%
0.42%
TTPH NewTETRAPHASE PHARMACEUTICALS I$1,306,00096,600
+100.0%
0.40%
ATRC NewATRICURE INC$1,295,00069,300
+100.0%
0.40%
ININ NewINTERACTIVE INTELLIGENCE GRO$1,010,00015,000
+100.0%
0.31%
SHPG NewSHIRE PLCsponsored adr$904,0006,400
+100.0%
0.28%
MDSO NewMEDIDATA SOLUTIONS INC$848,00014,000
+100.0%
0.26%
CBST NewCUBIST PHARMACEUTICALS INC$820,00011,900
+100.0%
0.25%
XOMA NewXOMA CORP DEL$818,000121,600
+100.0%
0.25%
SLXP NewSALIX PHARMACEUTICALS INC$809,0009,000
+100.0%
0.25%
CEMP NewCEMPRA INC$797,00064,300
+100.0%
0.25%
CSII NewCARDIOVASCULAR SYS INC DEL$782,00022,800
+100.0%
0.24%
PCRX NewPACIRA PHARMACEUTICALS INC$765,00013,300
+100.0%
0.24%
RGEN NewREPLIGEN CORP$732,00053,700
+100.0%
0.23%
BMRN NewBIOMARIN PHARMACEUTICAL INC$731,00010,400
+100.0%
0.22%
AMBI NewAMBIT BIOSCIENCES CORP$714,00074,100
+100.0%
0.22%
NTUS NewNATUS MEDICAL INC DEL$693,00030,800
+100.0%
0.21%
KPTI NewKARYOPHARM THERAPEUTICS INC$678,00029,600
+100.0%
0.21%
OMED NewONCOMED PHARMACEUTICALS INC$664,00022,500
+100.0%
0.20%
CERS NewCERUS CORP$631,00097,800
+100.0%
0.19%
HPTX NewHYPERION THERAPEUTICS INC$631,00031,200
+100.0%
0.19%
BRKR NewBRUKER CORP$605,00030,600
+100.0%
0.19%
ACRX NewACELRX PHARMACEUTICALS INC$599,00053,000
+100.0%
0.18%
INSM NewINSMED INC$560,00032,900
+100.0%
0.17%
TFX NewTELEFLEX INC$544,0005,800
+100.0%
0.17%
ATHN NewATHENAHEALTH INC$538,0004,000
+100.0%
0.17%
BLUE NewBLUEBIRD BIO INC$539,00025,700
+100.0%
0.17%
FEIC NewFEI CO$536,0006,000
+100.0%
0.16%
MDAS NewMEDASSETS INC$525,00026,500
+100.0%
0.16%
RPTP NewRAPTOR PHARMACEUTICAL CORP$526,00040,400
+100.0%
0.16%
MGNX NewMACROGENICS INC$521,00019,000
+100.0%
0.16%
MEIP NewMEI PHARMA INC$497,00062,100
+100.0%
0.15%
ECYT NewENDOCYTE INC$489,00045,700
+100.0%
0.15%
RMD NewRESMED INC$466,0009,900
+100.0%
0.14%
ATHX NewATHERSYS INC$443,000177,100
+100.0%
0.14%
SNSS NewSUNESIS PHARMACEUTICALS INC$435,00091,800
+100.0%
0.13%
NBIX NewNEUROCRINE BIOSCIENCES INC$360,00038,500
+100.0%
0.11%
HTWR NewHEARTWARE INTL INC$291,0003,100
+100.0%
0.09%
FMI NewFOUNDATION MEDICINE INC$274,00011,500
+100.0%
0.08%
ONTX NewONCONOVA THERAPEUTICS INC$264,00023,000
+100.0%
0.08%
VVUS NewVIVUS INC$253,00027,900
+100.0%
0.08%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2014-02-11
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q4 2013 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings